Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the effects of giving durvalumab alone or in
combination with tremelimumab on this type of cancer. In addition, this study will look at
the side effects of durvalumab when given alone or in combination with tremelimumab.